Pseudomonas aeruginosa in German intensive care units
Abstract number: 1733_158
Meyer E., Schwab F., Gastmeier P., Rueden H., Jonas D.
Objective: To analyse resistance data of Pseudomonas aeruginosa (PAE) in German ICUs participating in the project SARI (Surveillance of Antimicrobial use and antimicrobial Resistance in German Intensive Care Units.)
Methods: From 20002005 resistance rates in 45 ICUs were calculated and correlated with antibiotic use and structure parameters. Temporal changes were tested by Wilcoxon test for paired samples.
Results: A total of 7187 PAE were included. The mean resistance rate to imipenem was 22.9% (range 050.4), to piperacillin-tazobactam 21 (range 050.4), to ceftazidime 16.1 (055.6), to ciprofloxacin 17.1 (range 050.4), to meropenem 13.8 (range 0100). At 7% resistance to amicacin was lowest (range 068.6). Mean ceftazidime resistance increased significantly from 20002003 to 20042005 (from 14.6 to 18.8%) whereas amicacin resistance decreased from 8.2 to 4.5%. Ceftazidime resistance was significantly higher in hospitals with >1000 beds and resistance to amicacin was significantly higher in interdisciplinary ICUs. Carbapenem use correlated significantly and with a correlation coefficient >0.5 with imipenem, meropenem and ceftazidime resistance of PAE.
Conclusion: Over 20% of PAE in German ICUs are resistant to imipenem and piperacillin-tazobactam. This has not changed over the last 5 years. Carbapenem use and resistance correlate significantly.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|